Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Accounts Receivable : ¥15.01 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Chongqing Genrix Biopharmaceutical Co's accounts receivables for the quarter that ended in Mar. 2025 was ¥15.01 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Chongqing Genrix Biopharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 was 67.93.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Chongqing Genrix Biopharmaceutical Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2025 was ¥3.68.

Chongqing Genrix Biopharmaceutical Co Accounts Receivable Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Accounts Receivable Chart

Chongqing Genrix Biopharmaceutical Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Receivable

Get a 7-Day Free Trial

0.63

12.01

Chongqing Genrix Biopharmaceutical Co Quarterly Data
	Dec19	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Receivable	Get a 7-Day Free Trial												0.01	0.01	13.82	12.01	15.01

Chongqing Genrix Biopharmaceutical Co Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Chongqing Genrix Biopharmaceutical Co Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Chongqing Genrix Biopharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	15.005	/	20.156	*	91
=	67.93

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Chongqing Genrix Biopharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Chongqing Genrix Biopharmaceutical Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2025 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2402.658	+	0.75 * 15.005	+	0.5 * 52.978	-	1089.672
-	0	-	0)	/	366.680
=	3.68

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Chongqing Genrix Biopharmaceutical Co Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Chongqing Genrix Biopharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338

Website

http://www.genrixbio.com

Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

Executives

Jiang Ren Sheng

Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines